



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/683424/2010

European Medicines Agency decision

P/301/2010

of 22 December 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pollen from *dactylis glomerata* (8%), *lolium perenne* (8%), *phleum pratense* (8%), *poa pratensis* (8%), *anthoxanthum odoratum* (8%), *secale cereale* (10%), *betula pendula* (16,7%), *corylus avellana* (16,6%) and *alnus glutinosa* (16,6%), (EMA-000859-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/301/2010

of 22 December 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pollen from *dactylis glomerata* (8%), *lolium perenne* (8%), *phleum pratense* (8%), *poa pratensis* (8%), *anthoxanthum odoratum* (8%), *secale cereale* (10%), *betula pendula* (16,7%), *corylus avellana* (16,6%) and *alnus glutinosa* (16,6%), (EMEA-000859-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by ALK-Abelló A/S on 3 March 2010 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 November 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for pollen from dactylis glomarata (8%), lolium perenne (8%), phleum pratense (8%), poa pratensis (8%), anthoxanthum odoratum (8%), secale cereale (10%), betula pendula (16,7%), corylus avellana (16,6%) and alnus glutinosa (16,6%), oral solution, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for pollen from dactylis glomarata (8%), lolium perenne (8%), phleum pratense (8%), poa pratensis (8%), anthoxanthum odoratum (8%), secale cereale (10%), betula pendula (16,7%), corylus avellana (16,6%) and alnus glutinosa (16,6%), oral solution, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for pollen from dactylis glomarata (8%), lolium perenne (8%), phleum pratense (8%), poa pratensis (8%), anthoxanthum odoratum (8%), secale cereale (10%), betula pendula (16,7%), corylus avellana (16,6%) and alnus glutinosa (16,6%), oral solution, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to ALK-Abelló A/S, Bøge Allé 6-8, 2970 – Hørsholm, Denmark.

Done at London, 22 December 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/613946/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-000859-PIP01-10

Scope of the application

Active substance(s):

Pollen from dactylis glomarata (8%), lolium perenne (8%), phleum pratense (8%), poa pratensis (8%), anthoxanthum odoratum (8%), secale cereale (10%), betula pendula (16,7%), corylus avellana (16,6%) and alnus glutinosa (16,6%)

Condition(s):

Treatment of allergic rhinitis/rhino-conjunctivitis

Pharmaceutical form(s):

Oral solution

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

ALK-Abelló A/S

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, ALK-Abelló A/S submitted for agreement to the European Medicines Agency on 3 March 2010 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 April 2010.

Supplementary information was provided by the applicant on 23 August 2010.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation ,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 12 November 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan.

1. Waiver

1.1. Condition: Treatment of allergic rhinitis/ rhino-conjunctivitis

The waiver applies to:

All subsets of the paediatric population from birth to less than 5 years of age.

- for oral solution, sublingual use,
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s),
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of allergic rhinitis/ rhino-conjunctivitis

2.1.1. Indication(s) targeted by the PIP

Treatment of allergic rhinitis in patients with grass pollen allergy with or without mild to moderate allergic asthma

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Oral solution

2.1.4. Studies

Area	Number of studies	Description
Quality	-	Not applicable.
Non-clinical	-	Not applicable.
Clinical	1	Study 1 Randomized, placebo-controlled, double-blind parallel-group study to evaluate the long-term efficacy and safety/tolerability (3 years treatment and 2 years post-treatment follow-up) in children aged from 5 to less than 18 years with allergic rhinitis/ rhino-conjunctivitis in patients with grass pollen allergy with or without mild to moderate allergic asthma.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2030
Deferral for one or more studies contained in the paediatric investigation plan:	Yes